Dihydroergotamine Nasal Spray

157 interactions 472 cited references

Also sold as: Migranal Migranal® Nasal Spray Trudhesa Trudhesa® Nasal Spray

About Dihydroergotamine Nasal Spray

Dihydroergotamine is used to treat migraine headaches (severe, throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound and light). Dihydroergotamine is in a class of medications called ergot alkaloids. It works by tightening blood vessels in the brain and by stopping the release of natural… Read the full Dihydroergotamine Nasal Spray drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 10, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Troleandomycin Adagrasib Tucatinib Almotriptan Zolmitriptan Vasopressin

62 Contraindicated 79 Major 16 Moderate

All (157) Contraindicated (62) Major (79) Moderate (16)

Major

Dihydroergotamine Nasal Spray Abametapir Increased exposure of CYP3A4 substrate Details Dihydroergotamine Nasal Spray Alefacept Decreased dihydroergotamine plasma concentrations Details Dihydroergotamine Nasal Spray Apalutamide Erleada Reduced CYP3A4 substrate exposure Details Dihydroergotamine Nasal Spray Aprepitant Aponvie Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Asciminib Scemblix Increased CYP3A4 exposure and an increased risk of CYP3A4-related adverse reactions Details Dihydroergotamine Nasal Spray Avacopan Tavneos Increased exposure to CYP3A4 substrate Details Dihydroergotamine Nasal Spray Azithromycin AzaSite An increased risk of acute ergot toxicity (ergotism) Details Dihydroergotamine Nasal Spray Belzutifan Welireg Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Dihydroergotamine Nasal Spray Berotralstat Orladeyo Increased CYP3A4 substrate exposure and an increased CYP3A4 substrate-related adverse reactions Details Dihydroergotamine Nasal Spray Carbamazepine Carbatrol Reduced CYP3A4 substrate exposure and reduced efficacy of CYP3A4 substrate Details Dihydroergotamine Nasal Spray Ciprofloxacin Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Clofazimine Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Clotrimazole Aardora Anti-Fungal Maximum Strength Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Conivaptan Vaprisol Increased CYP3A substrate exposure Details Dihydroergotamine Nasal Spray Crizotinib Xalkori Increased dihydroergotamine exposure Details Dihydroergotamine Nasal Spray Dabrafenib Tafinlar Reduced sensitive CYP3A4 substrate exposure Details Dihydroergotamine Nasal Spray Daridorexant Increased CYP3A4 substrate with NTI exposure Details Dihydroergotamine Nasal Spray Dexfenfluramine Serotonin syndrome (confusion, mental status changes, diaphoresis, tremor, myoclonus, shivering, hyperreflexia, hypertension) Details Dihydroergotamine Nasal Spray Diltiazem Cardizem Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Dronedarone Multaq Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Duvelisib Copiktra Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Elinzanetant Lynkuet Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Dihydroergotamine Nasal Spray Enasidenib Idhifa Reduced CYP3A substrate exposure and reduced efficacy of CYP3A substrate Details Dihydroergotamine Nasal Spray Enzalutamide Xtandi Reduced CYP3A4 substrates with NTI exposure and reduced efficacy of CYP3A4 substrates with NTI Details Dihydroergotamine Nasal Spray Fedratinib Inrebic Increased CYP3A4 substrate exposure Details Dihydroergotamine Nasal Spray Fexinidazole An increased CYP3A4 substrate exposure Details Dihydroergotamine Nasal Spray Fluconazole Diflucan Increased plasma concentrations of ergot derivatives and increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Fluoxetine RECONCILE Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Fluvoxamine Increased ergot derivatives exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Fosnetupitant Increased exposure of CYP3A4 substrate Details Dihydroergotamine Nasal Spray Gepotidacin Blujepa Increased CYP3A4 substrate with NTI exposure Details Dihydroergotamine Nasal Spray Imatinib Gleevec Increased dihydroergotamine plasma concentrations and an increased risk of ergotism Details Dihydroergotamine Nasal Spray Isavuconazole Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Isavuconazonium Cresemba Increased dihydroergotamine exposure and an increased risk of ergotism (nausea, vomiting, vasospastic ischemia) Details Dihydroergotamine Nasal Spray Ivacaftor Kalydeco Increased CYP3A substrate exposure Details Dihydroergotamine Nasal Spray Lanreotide Altered exposure to CYP3A4 substrate Details Dihydroergotamine Nasal Spray Lazertinib Lazcluze Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Dihydroergotamine Nasal Spray Lefamulin Xenleta Increased sensitive CYP3A4 substrate exposure and an increased risk of sensitive CYP3A4 substrate-related toxicities associated wi... Details Dihydroergotamine Nasal Spray Lenacapavir Sunlenca Increased dihydroergotamine exposure Details Dihydroergotamine Nasal Spray Lorlatinib Lorbrena Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.